Research and Markets: Cambodia Pharmaceuticals and Healthcare Report Q4 2011

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/4c28ed/cambodia_pharmaceu) has announced the addition of the "Cambodia Pharmaceuticals and Healthcare Report Q4 2011" report to their offering.

Business Monitor International's Cambodia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Cambodia's pharmaceuticals and healthcare industry.

Cambodia will continue to remain unattractive to foreign pharmaceutical investors given its widespread corruption and low per-capita healthcare and pharmaceutical expenditure. Over the longterm, BMI expects pharmaceutical companies to take a greater interest in the country as they look for highgrowth frontier markets. However, this decision still depends on whether the government actively tries to improve its political situation and regulatory regime.

Headline Expenditure Projections

  • Pharmaceuticals: KHR812.33bn (US$194mn) in 2010 to KHR894.03bn (US$217mn) in 2011; +10.1% in local currency terms and +11.6% in US dollar terms. Forecast unchanged from Q311.
  • Healthcare: KHR3,036bn (US$725mn) in 2010 to KHR3,295bn (US$798mn) in 2011; +8.5% in local currency terms and +10.1% in US dollar terms. Forecast down slightly from Q311 due to macroeconomic factors.
  • Medical devices: KHR47.15bn (US$11mn) in 2010 to KHR51.06bn (US$12mn) in 2011; +8.3% in local currency terms and +9.8% in US dollar terms. Forecast unchanged from Q311, Business Environment Rating: Cambodia continues to rank last of the 18 pharmaceutical markets surveyed in the region.

Key Trends & Developments

  • In September 2011, Cambodia started a pilot project to contain the spread of malaria via text messaging and web-based technology. The project cut down the amount of time needed to report such epidemiological data to the district health level.
  • In the same month, India-based Himalaya Drug partnered with Thailand-based Berli Juncker to set up a plant in the country. Through the free trade agreement among South East Asian countries, its products will also be exported to Cambodia, Indonesia, the Philippines, Malaysia and Singapore.

Companies Mentioned:

  • PharmaProduct Manufacturing
  • Cambodia Pharmaceutical Enterprises
  • Sanofi (formerly Sanofi-Aventis)
  • Pfizer

For more information visit http://www.researchandmarkets.com/research/4c28ed/cambodia_pharmaceu

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716